Are PSA density and PSA density of the transition zone more accurate than PSA in predicting the pathological stage of clinically localized prostate cancer?

Urologic Oncology: Seminars and Original Investigations

Volumn 26, Issue 4, 2008, Pages 353-360

  Giannarini, Gianluca ^a   Scott, Cathryn A ^b   Moro, Umberto ^b   Pertoldi, Barbara ^b   Beltrami, Carlo A ^b   Selli, Cesare ^a  

^a UNIVERSITY OF PISA   (Italy)

^b UNIVERSITY OF UDINE   (Italy)

Author keywords

Gleason score; Multivariate analysis; Neoplasm staging; Prostate neoplasm; Prostate specific antigen; Transrectal ultrasound

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER LOCALIZATION; CANCER STAGING; DIAGNOSTIC ACCURACY; DISEASE SEVERITY; FALSE NEGATIVE RESULT; GLEASON SCORE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; LYMPH NODE DISSECTION; MAJOR CLINICAL STUDY; MALE; MATHEMATICAL COMPUTING; PELVIS LYMPH NODE; PREDICTION; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY;

AGED; HUMANS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS;

EID: 45849137499     PISSN: 10781439     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.urolonc.2007.04.002     Document Type: Article

References (30)

1. Partin A.W., Kattan M.W., Subong E.N., et al. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. JAMA 277 (1997) 1445-1451
2. D'Amico A.V., Whittington R., Malkowicz S.B., et al. Combined modality staging of prostate carcinoma and its utility in predicting pathologic stage and postoperative prostate specific antigen failure. Urology 49 3A Suppl (1997) 23-30
3. Wilkinson B.A., and Hamdy F.C. State-of-the-art staging in prostate cancer. BJU Int 87 (2001) 423-431
4. Benson M.C., Whang I.S., Olsson C.A., et al. The use of prostate specific antigen density to enhance the predictive value of intermediate levels of serum prostate specific antigen. J Urol 147 (1992) 817-821
5. Kalish J., Cooner W.H., and Graham Jr. S.D. Serum PSA adjusted for volume of transition zone (PSAT) is more accurate than PSA adjusted for total gland volume (PSAD) in detecting adenocarcinoma of the prostate. Urology 43 (1994) 601-606
6. Catalona W.J., Richie J.P., deKernion J.B., et al. Comparison of prostate specific antigen concentrations vs. prostate specific antigen density in the early detection of prostate cancer: Receiver operating characteristic curves. J Urol 152 (1994) 2031-2036
7. Cookson M.S., Floyd M.K., Ball Jr. T.P., et al. The lack of predictive value of prostate specific antigen density in the detection of prostate cancer in patients with normal rectal examinations and intermediate prostate specific antigen levels. J Urol 154 (1995) 1070-1073
8. Zlotta A.R., Djavan B., Marberger M., et al. Prostate specific antigen density of the transition zone: A new effective parameter for prostate cancer prediction. J Urol 157 (1997) 1315-1321
9. Lin D.W., Gold M.H., Ransom S., et al. Transition zone prostate specific antigen density: Lack of use in prediction of prostatic carcinoma. J Urol 160 (1998) 77-81
10. Horninger W., Reissigl A., Klocker H., et al. Improvement of specificity in PSA-based screening by using PSA-transition zone density and percent free PSA in addition to total PSA levels. Prostate 37 (1998) 133-137
11. Kikuchi E., Nakashima J., Ishibashi M., et al. Prostate specific antigen adjusted for transition zone volume. The most powerful method for detecting prostate carcinoma. Cancer 89 (2000) 842-849
12. Shinohara K., Wolf Jr. J.S., Narayan P., et al. Comparison of prostate specific antigen with prostate specific antigen density for three clinical applications. J Urol 152 (1994) 120-123
13. Wolff J.M., Boeckmann W., Effert P.J., et al. Clinical use of prostate-specific antigen and prostate-specific antigen density in the staging of patients with cancer of the prostate. Eur Urol 30 (1996) 451-457
14. Zlotta A.R., Djavan B., Petein M., et al. Prostate specific antigen density of the transition zone for predicting pathological stage of localized prostate cancer in patients with serum prostate specific antigen less than 10 ng/ml. J Urol 160 (1998) 2089-2095
15. Kurita Y., Suzuki A., Masuda H., et al. Transition zone volume-adjusted prostate-specific antigen value predicts extracapsular carcinoma of the prostate in patients with intermediate prostate-specific antigen levels. Eur Urol 33 (1998) 32-38
16. Horninger W., Rogatsch H., Reissigl A., et al. Correlation between preoperative predictors and pathologic features in radical prostatectomy specimens in PSA-based screening. Prostate 40 (1999) 56-61
17. Catalona W.J., Southwick P.C., Slawin K.M., et al. Comparison of percent free PSA, PSA density, and age-specific PSA cutoffs for prostate cancer detection and staging. Urology 56 (2000) 255-260
18. Furuya Y., Ohta S., Sato N., et al. Prostate-specific antigen density adjusted for the transition zone for staging clinically localized prostate cancer in Japanese patients with intermediate serum prostate-specific antigen levels. Anticancer Res 21 (2001) 1317-1320
19. Horiguchi A., Nakashima J., Horiguchi Y., et al. Prediction of extraprostatic cancer by prostate specific antigen density, endorectal MRI, and biopsy Gleason score in clinically localized prostate cancer. Prostate 56 (2003) 23-29
20. Brassell S.A., Kao T.C., Sun L., et al. Prostate-specific antigen vs. prostate-specific antigen density as predictor of tumor volume, margin status, pathologic stage, and biochemical recurrence of prostate cancer. Urology 66 (2005) 1229-1233
21. Nathan M.S., Seenivasagam K., Mei Q., et al. Transrectal ultrasonography: Why are estimates of prostate volume and dimension so inaccurate?. Br J Urol 77 (1996) 401-407
22. Baltaci S., Yagci C., Aksoy H., et al. Determination of transition zone volume by transrectal ultrasound in patients with clinically benign prostatic hyperplasia: Agreement with enucleated prostate adenoma weight. J Urol 164 (2000) 72-75
23. Dähnert W.F. Determination of prostate volume with transrectal US for cancer screening. Radiology 183 (1992) 625-626
24. Tong S., Cardinal H.N., McLoughlin R.F., et al. Intra- and inter-observer variability and reliability of prostate volume measurement via two-dimensional and three-dimensional ultrasound imaging. Ultrasound Med Biol 24 (1998) 673-681
25. Walsh P.C., Lepor H., and Eggleston J.C. Radical prostatectomy with preservation of sexual function: Anatomical and pathological considerations. Prostate 4 (1983) 473-485
26. Sobin L.H., and Wittekind C. TNM classification of malignant tumors. 5th ed. (1997), Wiley-Liss, New York 170-173
27. Djavan B. PSA and repeat biopsy. In: Brawer M.K. (Ed). Prostate specific antigen (2001), Marcel Dekker, New York 159-174
28. Sebo T.J., Bock B.J., Cheville J.C., et al. The percent of cores positive for cancer in prostate needle biopsy specimens is strongly predictive of tumor stage and volume at radical prostatectomy. J Urol 163 (2000) 174-178
29. Grossklaus D.J., Coffey C.S., Shappell S.B., et al. Percent of cancer in the biopsy set predicts pathological findings after prostatectomy. J Urol 167 (2002) 2032-2036
30. Lewis Jr. J.S., Vollmer R.T., and Humphrey P.A. Carcinoma extent in prostate needle biopsy tissue in the prediction of whole gland tumor volume in a screening population. Am J Clin Pathol 118 (2002) 442-450